CCs are Only for Back Slapping and Tooting Your Own Horn?
Sunil, hold a CC and let shareholders know what is going on. What are the options on the table?
If Probuphine were approved you would have had a CC to cackle and bask in congratulatory analyst fawns.
It is more important to hold a CC after the FDA denial and inform shareholders about the avenues available to the company, the time frames, the financial situation, the Braeburn relationship now, the Huckel resignation, thoughts on downsizing, sale of the company..........
Sunil tends to disappear at a time when shareholders need answers and when leadership is needed,.
I would like to hear their interpretation of what the FDA wants.
Is an appeal an option? How long would that take? 3 months? 6 months?
Can they refile the NDA with minor modifications?
If additional trials are needed, how long would that take?
Can Braeburn float them a loan as an advance against future royalties, if additional funds are needed?
What is Braeburns take on the situation?
Who will pay the expenses needed to satisfy the FDA?
There are a host of questions that they can address before getting input from the FDA.
Be a man, Sunil, and face shareholders.
This is the time to step up to the plate.